Extended-release trazodone in the treatment of major depressive disorder
Makaleler > Derleme · 2019
Yazarlar: Oguz Karamustafalioglu, Nesrin Dilbaz, Ali Caykoylu, Tunc Alkin, Ali Saffet GÖNÜL, Murad Atmaca
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2019, cilt 20, ss 453-453
Özet
Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.